# Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

> **NCT01489059** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 42 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** BMS-982470 (recombinant interleukin-21)
- **BIOLOGICAL:** BMS-982470 (recombinant interleukin-21)
- **BIOLOGICAL:** BMS-982470 (recombinant interleukin-21)
- **BIOLOGICAL:** BMS-982470 (recombinant interleukin-21)
- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT01489059
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2014-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01489059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01489059, "Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01489059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*